Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer.1999;83:18-29.
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer.1999;80:827-841.
Kitchener HC, Symonds P. Detection of cervical intraepithelial neoplasia in developing countries. Lancet.1999;353:856-857.
Sitas F, Bezwoda WR, Levin V.
et al. Association between human immunodeficiency virus type 1 infection and
cancer in the black population of Johannesburg and Soweto, South Africa. Br J Cancer.1997;75:1704-1707.
Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa. AIDS.1999;13:2563-2570.
International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans.
Vol 64. Human Papillomaviruses.Lyon, France: IARC; 1995.
Wright Jr TC, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic
screening to detect cervical cancer. JAMA.2000;283:81-86.
Sankaranarayanan R, Wesley R, Somanathan T.
et al. Visual inspection of the uterine cervix after the application of acetic
acid in the detection of cervical carcinoma and its precursors. Cancer.1998;83:2150-2156.
Visual inspection with acetic acid for cervical-cancer screening. Lancet.1999;353:869-873.
Womack SD, Chirenje ZM, Gaffikin L.
et al. HPV-based cervical cancer screening in a population at high risk for
HIV infection. Int J Cancer.2000;85:206-210.
Denny L, Kuhn L, Pollack A.
et al. Evaluation of alternative methods of cervical cancer screening for
resource-poor settings. Cancer.2000;89:826-833.
Schiffman M, Hildesheim A, Herrero R, Bratti C. Human papillomavirus testing as a screening tool for cervical cancer. JAMA.2000;283:2525-2526.
Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
Ho GY, Bierman R, Beardsley L.
et al. Natural history of cervicovaginal papillomavirus infection in young
women. N Engl J Med.1998;338:423-428.
Ho GY, Burk RD, Klein S.
et al. Persistent genital human papillomavirus infection as a risk factor
for persistent cervical dysplasia. J Natl Cancer Inst.1995;87:1365-1371.
Remmink A, Walboomers J, Helmerhorst T.
et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical
lesions is associated with progressive disease. Int J Cancer.1995;61:306-311.
Sun XW, Kuhn L, Ellerbrock TV.
et al. Human papillomavirus infection in women infected with the human immunodeficiency
virus. N Engl J Med.1997;337:1343-1349.
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ.
et al. Relation of human papillomavirus status to cervical lesions and consequences
for cervical-cancer screening. Lancet.1999;354:20-25.
Moscicki AB, Shiboski S, Broering J.
et al. The natural history of human papillomavirus infection as measured by
repeated DNA testing in adolescent and young women. J Pediatrics.1998;132:277-284.
Londesborough P, Ho L, Terry G.
et al. Human papillomavirus genotype as a predictor of persistence and development
of high-grade lesions in women with minor cervical abnormalities. Int J Cancer.1996;69:364-368.
Hildesheim A, Schiffman MH, Gravitt PE.
et al. Persistence of type-specific human papillomavirus infection among cytologically
normal women. J Infect Dis.1994;169:235-240.
Rozendaal L, Walboomers JM, van der Linden JC.
et al. PCR-based high-risk HPV test in cervical cancer screening gives objective
risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer.1996;68:766-769.
Wallin KL, Wiklund F, Angstrom T.
et al. Type-specific persistence of human papillomavirus DNA before the development
of invasive cervical cancer. N Engl J Med.1999;341:1633-1638.
Herrero R, Hildesheim A, Bratti C.
et al. Population-based study of human papillomavirus infection and cervical
neoplasia in rural Costa Rica. J Natl Cancer Inst.2000;92:464-474.
Palefsky JM, Minkoff H, Kalish LA.
et al. Cervicovaginal human papillomavirus infection in human immunodeficiency
virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst.1999;91:226-236.
Andersen ES, Husth M. Cryosurgery for cervical intraepithelial neoplasia: 10-year follow-up. Gynecol Oncol.1992;45:240-242.
Creasman WT, Hinshaw WM, Clarke-Pearson DL. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol.1984;63:145-149.
Olatunbosun OA, Okonofua FE, Ayangade SO. Outcome of cryosurgery for cervical intraepithelial neoplasia in a
developing country. Int J Gynaecol Obstet.1992;38:305-310.
Mitchell MF, Tortolero-Luna G, Cook E.
et al. A randomized clinical trial of cryotherapy, laser vaporization, and
loop electrosurgical excision for treatment of squamous intraepithelial lesions
of the cervix. Obstet Gynecol.1998;92:737-744.
Denny L. An Evaluation of Alternative Strategies for the Prevention
of Cervical Cancer in Low Resource Settings [thesis]. Cape Town, South Africa: University of Cape Town and Groote Schuur
Hospital; May 2000.
Cuzick J, Sasieni P, Davies P.
et al. A systematic review of the role of human papillomavirus testing within
a cervical screening programme. Health Technol Assess.1999;3:1-204.
Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst.1999;91:252-258.
Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol.1993;12:186-192.
McCrory D, Mather D, Bastain L.
et al. Evaluation of Cervical Cytology. Evidence Report/Technology
Assessment No.5 (Prepared by Duke University under Contract No. 290-97-0014). Rockville, Md: Agency for Health Care Policy and Research. February
1999. AHCPR Pub No. 99-E010.
Ponten J, Adami HO, Bergstrom R.
et al. Strategies for global control of cervical cancer. Int J Cancer.1995;60:1-26.
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus
infection and cervical carcinogenesis. Am J Epidemiol.2000;151:1158-1171.
Sherlaw-Johnson C, Gallivan S, Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int J Cancer.1997;72:210-216.
Syrjanen K, Kataja V, Yliskoski M.
et al. Natural history of cervical human papillomavirus lesions does not substantiate
the biologic relevance of the Bethesda system. Obstet Gynecol.1992;79:675-682.
Koutsky L, Holmes K, Critchlow C.
et al. A cohort study of the risk of cervical intraepithelial neoplasia grade
2 or 3 in relation to human papillomavirus infection. N Engl J Med.1992;327:1272-1278.
Jenkins D, Sherlaw-Johnson C, Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int J Cancer.1996;65:768-773.
Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-
resource settings. J Natl Cancer Inst.2000;92:818-825.
Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol.1995;141:680-689.
Nanda K, McCrory DC, Myers ER.
et al. Accuracy of the Papanicolaou test in screening for and follow-up of
cervical cytologic abnormalities. Ann Intern Med.2000;132:810-819.
Nene BM, Deshpande S, Jayant K.
et al. Early detection of cervical cancer by visual inspection. Int J Cancer.1996;68:770-773.
Cuzick J, Beverley E, Ho L.
et al. HPV testing in primary screening of older women. Br J Cancer.1999;81:554-558.
Clavel C, Masure M, Bory JP.
et al. Hybrid Capture II-based human papillomavirus detection, a sensitive
test to detect in routine high-grade cervical lesions. Br J Cancer.1999;80:1306-1311.
Hillemanns P, Kimmig R, Huttemann U.
et al. Screening for cervical neoplasia by self-assessment for human papillomavirus
Sellors JW, Lorincz AT, Mahony JB.
et al. Comparison of self-collected vaginal, vulvar and urine samples with
physician-collected cervical samples for humanpapillomavirus testing to detect
high-grade squamous intraepithelial lesions. CMAJ.2000;163:513-518.
Harper D, Hildesheim A, Cobb J, Greenberg M, Vaught J, Lorincz A. Collection devices for human papillomavirus. J Fam Pract.1999;48:531-535.
Denny L, Kuhn L, Risi L.
et al. Two-stage cervical cancer screening. Am J Obstet Gynecol.2000;183:383-388.
Sankaranarayanan R, Black RJ, Swaminathan R, Parkin DM. An overview of cancer survival in developing countries. IARC Sci Publ.1998;145:135-173.
Rogo KO, Omany J, Onyango JN, Ojwang SB, Stendahl U. Carcinoma of the cervix in the African setting. Int J Gynaecol Obstet.1990;33:249-255.
Pettersson F, Bjorkholm E, Naslund I. Evaluation of screening for cervical cancer in Sweden. Int J Epidemiol.1985;14:521-527.
Surveillance, Epidemiology, End Results (SEER) Cancer Statistics
Review, 1973-1994. Bethesda, Md: US DHHS, PHS, NIH, NCI. Available at:
http://www-seer.ims.nci.nih.gov/: National Cancer Institute; 1997. Accessibility verified June 4, 2001.
Longini I, Clark W, Byers R.
et al. Statistical analysis of the stages of HIV infection using a Markov
model. Stat Med.1989;8:831-843.
Enger C, Graham N, Peng Y.
et al. Survival from early, intermediate, and late stages of HIV infection. JAMA.1996;275:1329-1334.
Freedberg K, Scharfstein J, Seage G.
et al. The cost-effectiveness of preventing AIDS-related complications. JAMA.1997;279:130-136.
The 1988 Bethesda System for reporting cervical/vaginal cytological
diagnoses. National Cancer Institute Workshop. JAMA.1989;262:931-934.
Ellerbrock TV, Chiasson MA, Bush TJ.
et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected
Serwadda D, Wawer MJ, Shah KV.
et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural
Uganda for detection of human papillomavirus. J Infect Dis.1999;180:1316-1319.
Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. Int J Gynaecol Obstet.1999;65:243-249.
Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost-effectiveness of screening for
cervical cancer in HIV-infected women. Ann Intern Med.1999;130:97-107.
Medical Association of South Africa. 1999 Guide to Fees for Medical Services. Pinelands, South Africa: MASA Multimedia; 1999.
Central Statistical Service, Republic of South Africa. South Africa Living Standards and Development Survey. Statistical Release; 1997. Pretoria, South Africa: Government Printer;
Central Statistical Service, Republic of South Africa. 1994 Household Survey. Statistical Release; 1997. Pretoria, South Africa: Government Printer; 1994.
Central Statistical Service, Republic of South Africa. Consumer Price Index. Statistical Release; 1997. Pretoria, South Africa: Government Printer;
Mandelblatt J, Fryback D, Weinstein M.
et al. Assessing the effectiveness of health interventions for cost-effectiveness
analysis. J Gen Intern Med.1997;12:551-557.
Bailie RS, Selvey CE, Bourne D, Bradshaw D. Trends in cervical cancer mortality in South Africa. Int J Epidemiol.1996;25:488-493.
Mathers C, Sadana R, Salomon J, Murray C, Lopez A. Estimates of DALE for 191 Countries: Methods and results, Global Programme
on Evidence for Health Policy Working Paper No.16. World Health Organization, June 2000. Available at:
Accessed May 29, 2001.
Dorrington R, Bradshaw D, Wegner T. Estimates of the level and shape of mortality rates in South Africa
around 1985 and 1990 derived by applying indirect demographic techniques to
reported deaths. Parow, South Africa: Centre for Epidemiological Research in Southern
Africa Medical Research Council; 1999 Technical Report.
Grant A, Djomand G, DeCock K. Natural history and spectrum of disease in adults with HIV/AIDS in
Africa. AIDS.1997;11(suppl B):S43-S54.
Ballegooijen M, Koopmanschap M, Tjokrowardojo Subandono A, Oortmarssen G. Care and costs of advanced cervical cancer. Eur J Cancer.1992;28A:1703-1708.
Cost-comparison study of several medical procedures and radiation therapy
at the University of Cape Town. Cape Town, South Africa: Dept of Radiation Therapy, University of
Cape Town; 1993. Internal Report.
Peters D, Elmendorf A, Kandola K, Chellaraj G. Benchmarks for health expenditures, services and outcomes in Africa
during the 1990's. Bull World Health Organ.2000;78:761-769.
Sitas F. Histologically diagnosed cancers in South Africa, 1988. S Afr Med J.1994;84:344-348.
World Bank. World Bank development report 1993: investing in health. New York, NY: Oxford University press 1993. From: World Bank. Confronting AIDS: Public Priorities in a Global Epidemic.
New York, NY: Oxford University Press, 1997.
Gilson L, Mkanje R, Grosskurth H.
et al. Cost-effectiveness of improved treatment services for sexually transmitted
diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet.1997;350:1805-1809.